breast cancer cell lines. Of seven PIK3CA-mutant breast cancer lines, six were responsive to BYL719 ( fig. S15 ). In addition to their characteristic PIK3CA mutation, two lines harbored mutations of unknown importance in FGFR4 (Y367C; MDA-MB-453 cells) and in FGFR2 (K570E; EFM-19 cells).
The former showed cooperative cytotoxicity by BYL719 and AZD4547, whereas the latter was insensitive to FGFR inhibition ( fig. S15) . One of five PIK3CA-mutant breast cancer lines without an FGFR gene mutation showed modest sensitivity to AZD4547 (CAL51), whereas the other four were resistant. Thus, the combination of genotyping and functional testing for drug susceptibility is essential to defining therapeutically relevant driver mutations in both breast cancer cell lines and CTC cultures.
In vitro screening of additional drugs for cooperation with PIK3CA-targeted agents identified inhibitors of the insulin-like growth factor receptor 1 (IGF1R, inhibitors OSI906 and BMS754807) and HSP90 (inhibitor STA9090, Ganetespib) (Fig. 3C ). Although neither of these is mutated in BRx-07 cells, IGF1R has been implicated in modulating signaling loops that mitigate sensitivity to PI3K inhibitors (24) , and HSP90 is involved in stabilization of mutant kinases (20) . To extend drug sensitivity studies to mouse xenografts, we generated BRx-07-derived mammary tumors and treated these with BYL719, AZD4547, the two agents in combination, or diluent control. In vivo tumor suppression was observed after treatment with either drug individually, whereas the combination completely abrogated tumor growth (Fig. 3D) .
In this proof-of-concept study, we have shown that the culture of tumor cells circulating in the blood of patients with breast cancer provides an opportunity to study patterns of drug susceptibility, linked to the genetic context that is unique to an individual tumor. In patients with hormoneresponsive breast cancer, most of whom have bone metastases that are not readily biopsied, the ability to noninvasively and repeatedly analyze live tumor cells shed into the blood from multiple metastatic lesions may enable monitoring of emerging subclones with altered mutational and drug sensitivity profiles. The successful culture of CTCs stems partly from the application of a microfluidic device capable of effectively depleting leukocytes from a blood specimen while preserving viable tumor cells for ex vivo expansion (3). The proliferation of cultured CTCs as nonadherent spheres differs from that of characteristic epithelial cancer cell cultures and may reflect intrinsic properties of tumor cells that remain viable in the bloodstream after loss of attachment to basement membrane. A recent report documented direct inoculation of the mouse femur with blood-derived cancer cells from a patient who had very high numbers of CTCs, but in vitro culture was not successful (25) . Our results differ from the adherent in vitro CTC cultures described by Zhang et al. (26) , but these lines appear to share the identical TP53, BRAF, and KRAS genotype of the highly tumorigenic MDA-MB-231 cell line.
Optimization of CTC culture conditions will be needed before this strategy can be incorporated into clinical practice. In addition, further characterization of the nonadherent CTC-derived cell lines described here will be required to define how they differ from cells cultured from primary tumor biopsies or directly implanted into mouse models (4, 14) . In the future, strategies such as that described here may be an essential component of "precision medicine" in oncology, where treatment decisions are based on evolving tumor mutational profiles and drug sensitivity patterns in individual patients. Program Thomas G. Bernhardt,
Peptidoglycan (PG) is a polysaccharide matrix that protects bacteria from osmotic lysis. Inhibition of its biogenesis is a proven strategy for killing bacteria with antibiotics.The assembly of PG requires disaccharide-pentapeptide building blocks attached to a polyisoprene lipid carrier called lipid II. Although the stages of lipid II synthesis are known, the identity of the essential flippase that translocates it across the cytoplasmic membrane for PG polymerization is unclear. We developed an assay for lipid II flippase activity and used a chemical genetic strategy to rapidly and specifically block flippase function. We combined these approaches to demonstrate that MurJ is the lipid II flippase in Escherichia coli.
B acteria use polyisoprenoid-linked oligosaccharides to assemble the essential peptidoglycan (PG) matrix that surrounds their cytoplasmic membrane and fortifies their cell envelope against high internal osmotic pressure (1) . The building block of PG is a disaccharide-pentapeptide that is synthesized at the cytoplasmic leaflet of the inner membrane (IM) as a precursor known as lipid II (Fig. 1A) (1, 2) . This precursor must be flipped across the membrane for cell wall synthesis. The identity of the lipid II flippase has been controversial, with the debate centered on two candidates: MurJ-like and FtsW/RodA-like proteins (3) (4) (5) (6) . MurJ is a polytopic IM protein and a member of the MOP (multidrug/oligo-saccharidyllipid/polysaccharide) exporter superfamily (7) . It is essential in Escherichia coli. Cells depleted of MurJ fail to complete PG biogenesis, accumulate PG precursors, and lyse (4, 6) . A threedimensional structural model and corresponding transmembrane topology of MurJ are similar to those of MOP exporters of amphipathic drugs and undecaprenyl-PP-linked oligosaccharides (8) . Furthermore, a hydrophilic central cavity in MurJ is essential for function. FtsW and its paralog RodA are polytopic IM proteins that belong to the SEDS (shape, elongation, division, and sporulation) superfamily and are required for PG synthesis during division (FtsW) or elongation (RodA) (3, 5, 9) . Support for SEDS proteins functioning as flippases is based on in vitro studies in which lipid II flippase activity was detected for purified FtsW incorporated into liposomes (10) .
The identity of the lipid II flippase has been sought after for decades (2) . Determining which proteins flip lipid II in vivo requires a sensitive method to detect lipid II flippase activity and a method to connect this activity to a specific protein within the cell. When added to E. coli, the protein toxin colicin M (ColM) is translocated into the periplasm, where it cleaves lipid II (Fig. 1A) (11, 12). We therefore reasoned that ColM could be used in an assay to detect freshly flipped lipid II. To evaluate this possibility, cells were metabolically labeled with [ 3 H]-mDAP, an amino acid unique to the PG peptide, and either left untreated or incubated with purified ColM. Cells were then extracted with hot water followed by butanol to separate water-soluble PG intermediates and ColM-derived products from lipid-linked PG precursors. Highperformance liquid chromatography (HPLC) analysis of the water-soluble extract revealed a new peak in the ColM-treated samples (Fig. 1B and  fig. S1 ), and its appearance correlated with the loss of radiolabel in the butanol extract (Fig. 1C) . Moreover, increasing the cellular lipid II concentration by overproducing the lipid-carrier synthase UppS (2) enhanced the production of the ColM-specific peak ( fig. S2 ). The ColM-specific product was identified as PP-M pep4 -G (figs. S3 and S4), which presumably results from the processing of the ColM product, PP-M pep5 -G, by a carboxypeptidase (Fig. 1A) . Because carboxypeptidases function only in the periplasm (1), this result confirms that ColM acts on flipped lipid II.
To test whether MurJ flips lipid II, a method to rapidly and specifically inactivate it was needed. A collection of 39 functional single-Cys MurJ variants modifiable by the Cys-reacting molecule MTSES (2-sulfonatoethyl methanethiosulfonate) was previously used to determine the membrane topology of MurJ (8) . We asked whether any of these mutant proteins were rendered nonfunctional by derivitization with MTSES. Treatment of Cys-free MurJ (MurJ WT ) cells with MTSES had no effect on growth, but the addition of MTSES to cells producing derivatives with Cys substitutions SCIENCE sciencemag.org ]-mDAP. cps, counts per second. After 15 min, ColM and/or MTSES were added as indicated, and growth was continued for 10 min. Samples were then withdrawn and either extracted with hot water alone or sequentially with water, then butanol. Hot-water extracts were subjected to HPLC and radiodetection to quantify the labeled ColM product (B); scintillation counting was used to quantify label in the lipid (butanol) fraction (C). See figs. S1 to S4 for experimental details and peak identification. Shown are the mean T SD from three experiments. P value determined with Student's t test. N.S., not significant. at positions 29, 49, 263, and 269 rapidly induced lysis, suggesting that MurJ function, and thus PG synthesis, was inhibited ( Fig. 2 and fig. S5 ).
In contrast, treatment of MurJ E273C cells with MTSES caused cell shape defects and limited lysis indicative of an incomplete PG synthesis block due to partial MurJ inhibition. The toxicity of MTSES labeling was suppressed in all five strains by the presence of the wild-type murJ allele (Fig. 2 and fig. S5 ). Thus, MTSES specifically and rapidly inhibits these single-Cys MurJ variants. We chose MurJ A29C (Fig. 2 , and figs. S6 and S7) to assess the effect of MurJ inactivation on lipid II flipping.
This chemical genetic method for MurJ inactivation was compatible with the in vivo flippase assay. MTSES treatment of MurJ WT cells did not affect lipid II processing by ColM (Fig. 1, B and  C, and fig. S1 ). Additionally, in the absence of MTSES, MurJ A29C cells behaved like MurJ WT cells (Fig. 1, B and C, and fig. S1 ). However, simultaneous addition of MTSES and ColM to MurJ A29C cells failed to produce significant quantities of the ColM-dependent product PP-M pep4 -G. In fact, radiolabel in the lipid fraction increased in these samples (Fig. 1, B and C, and fig. S1 ). Thus, when MurJ A29C was inactivated with MTSES, lipid II was protected from ColM cleavage, and label accumulated in the lipid fraction as observed previously for MurJ-depletion strains (4, 6) .
The protection of lipid II from ColM cleavage upon MurJ A29C inactivation suggests that either lipid II is not flipped or that inhibiting MurJ A29C somehow interferes with ColM import or activity. To investigate this, we performed our assay using spheroplasting to remove the outer membrane (OM) barrier (13) (Fig. 3) . Moreover, lysis of MTSES-treated MurJ A29C spheroplasts restored lipid II processing, indicating that the intact IM impeded the access of ColM to lipid II. Thus, MurJ appears to act as a lipid II flippase.
When MurJ A29C was inactivated with MTSES, flippase activity was reduced to a level that was barely detectable and was incompatible with life. This observation indicates that the essential function of MurJ is to translocate lipid II and that other factors catalyzing lipid II flipping are unlikely to exist in E. coli. Nevertheless, we investigated the requirement of SEDS proteins for flippase activity by depleting FtsW in a DrodA strain. We found that lipid II flipping remained robust in this background (figs. S8 and S9). Although it is possible that residual FtsW in these cells was sufficient for the observed activity, this result suggests that SEDS proteins are not responsible for lipid II flippase activity in vivo. Alternatively, the decrease in levels of PG lipid intermediates upon FtsW depletion ( fig. S9 ) suggests that either synthesis of PG precursors or recycling of undecaprenyl-P might be affected by the loss of SEDS activity. From these data and the fact that MurJ contains a central solvent-exposed cavity that is essential for function (8), we conclude that MurJ is the lipid II flippase in E. coli. In all but one case, spheroplasts were pelleted and resuspended in ColM reaction buffer with sucrose, and MTSES (0.8 mM) was added as indicated. The lysis + sample was resuspended in buffer lacking sucrose to lyse the spheroplasts. ColM (100 mg) was added to the prepared spheroplasts as indicated, and they were incubated for 15 min at 37°C. Lipid intermediates were detected by scintillation counting after butanol extraction. Statistics are as for Fig. 1 . cpm, counts per minute.
